ACETAMINOPHEN | N206610 | RISING PHARMA HOLDING INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | Pfizer | 22 | 2026-03-31 → 2027-01-27 | |
| Phase 3 | Active | Hoffmann-La Roche | 271 | 2020-08-10 → 2031-03-02 | |
| Phase 1 | Active | AstraZeneca | 100 | 2025-06-04 → 2027-07-09 | |
| Phase 3 | Active | Sanofi | 337 | 2020-06-16 → 2033-10-21 | |
| Phase 2 | Active | University of Miami | 310 | 2020-02-11 → 2027-02-01 | |
| Phase 3 | Active | Merck Sharp & Dohme LLC | 550 | 2024-06-11 → 2030-06-14 | |
| Phase 1 | Active | Baylor College of Medicine | 68 | 2009-04 → 2031-04 | |
| N/A | Active | University of Florida | 100 | 2025-01-29 → 2026-10 | |
| Phase 3 | Active | Hoffmann-La Roche | 142 | 2021-06-25 → 2027-12-21 | |
| Phase 2 | Active | Seoul National University Bundang Hospital | 90 | 2025-11-21 → 2026-12-25 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
15 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jan 19, 2021 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.